The Guardian reports that AstraZeneca have expressed caution about the year ahead, posting an expected 4% drop in full-year operating profit to $8.1bn. Excluding costs from restructuring and the 2007 acquisition of MedImmune, operating profits for the year were up 8%.
http://www.guardian.co.uk/business/2008/feb/01/astrazenecabusiness.biochemistrymolecularbiology
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment